PDCD1 and ovarian cancer: In a recent clinical trial testing the safety and efficacy of nivolumab, a fully human anti-PD-1 antibody, in 20 ovarian cancer patients, the best overall response was 15% in the cohort receiving a high-dose of nivolumab intravenously including a complete response in two cases [8].